• Users Online: 314
  • Print this page
  • Email this page
Year : 2022  |  Volume : 16  |  Issue : 2  |  Page : 216-219

Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study

1 Division of Nephrology, Superspecialty Hospital, Government Medical College, Srinagar, Jammu and Kashmir, India
2 Division of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
3 Division of Nephrology, ASCOMS Hospital, Jammu, Jammu and Kashmir, India
4 Department of Medicine, Government Medical College, Baramula, Jammu and Kashmir, India
5 Department of Pharmacy Practice, Nova College of Pharmaceutical Education and Research, Hyderabad, Telangana, India
6 Flushing Hospital Medical Center, New York, USA

Correspondence Address:
Dr. Muzamil Latief
Division of Nephrology, Superspecialty Hospital, Government Medical College, Srinagar - 190 010, Jammu and Kashmir
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijot.ijot_54_21

Rights and Permissions

Introduction: Remdesivir has shown broad-spectrum antiviral activity. This drug is approved by the Food and Drug Administration for coronavirus disease 2019 (COVID-19) management. Other than a few case series and case reports, not much information is available on its use in kidney transplant recipients (KTRs). Materials and Methods: We describe our experience of seven KTRs with COVID-19. All the patients were hypoxemic. High-resolution computed tomography (CT) chest was done in all the patients. Injection remdesivir 200 mg on day 1 followed by 100 mg daily was given for a maximum of 5 days irrespective of estimated glomerular filtration rate (eGFR). Observations and Results: Mean age of patients was 46.28 ± 10.41 years and one patient was female. Mean CT severity score was 15. In our study, 2 patients who required mechanical ventilation expired. None of our patient had worsening of acute kidney injury (AKI) or new-onset AKI after institution of remdesivir. Discussion: Optimal management for this patient population remains unknown, therefore, treatment of COVID-19 in KTRs varies from center to center. The studies on remdesivir use in KTRs with COVID-19 are not extensive. Our series does indicate safety of remdesivir in KTRs. Conclusion: We observed that remdesivir can be used in KTRs with COVID-19 with hypoxemia irrespective of eGFR. We suggest that large-scale studies should be done to substantiate these findings.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal